Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 8.5% during the second quarter, HoldingsChannel reports. The fund owned 33,166 shares of the company’s stock after selling 3,063 shares during the period. California State Teachers Retirement System’s holdings in Pliant Therapeutics were worth $966,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in PLRX. Nuveen Asset Management LLC grew its holdings in Pliant Therapeutics by 247.4% during the first quarter. Nuveen Asset Management LLC now owns 80,277 shares of the company’s stock worth $3,157,000 after acquiring an additional 57,172 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Pliant Therapeutics during the first quarter worth $8,423,000. Royal Bank of Canada grew its holdings in Pliant Therapeutics by 829.3% during the first quarter. Royal Bank of Canada now owns 2,128 shares of the company’s stock worth $84,000 after acquiring an additional 1,899 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in Pliant Therapeutics during the first quarter worth $3,003,000. Finally, Millennium Management LLC grew its holdings in Pliant Therapeutics by 99.3% during the first quarter. Millennium Management LLC now owns 63,366 shares of the company’s stock worth $2,492,000 after acquiring an additional 31,570 shares during the period. 85.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:PLRX opened at $15.02 on Thursday. Pliant Therapeutics, Inc. has a 52-week low of $13.81 and a 52-week high of $43.92. The stock’s fifty day simple moving average is $17.06 and its 200-day simple moving average is $22.42. The company has a market capitalization of $541.31 million, a P/E ratio of -5.84 and a beta of 1.00.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings data on Tuesday, November 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.06). Pliant Therapeutics had a negative net margin of 914.12% and a negative return on equity of 36.28%. Sell-side analysts forecast that Pliant Therapeutics, Inc. will post -2.73 EPS for the current year.

Several analysts have weighed in on the company. Zacks Investment Research lowered Pliant Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 13th. Royal Bank of Canada assumed coverage on Pliant Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $38.00 target price on the stock. HC Wainwright assumed coverage on Pliant Therapeutics in a report on Wednesday, November 3rd. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Needham & Company LLC assumed coverage on Pliant Therapeutics in a report on Tuesday, August 10th. They issued a “buy” rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pliant Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $44.00.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Further Reading: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding PLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pliant Therapeutics, Inc. (NASDAQ:PLRX).

Institutional Ownership by Quarter for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.